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Abstract
In the healthy gastrointestinal tract, homeostasis is an active process that requires a careful balance
of host responses to the enteric luminal contents. Intestinal macrophages and dendritic cells
comprise a unique group of tissue immune cells that are ideally situated at the interface of the host
and the enteric luminal environment to appropriately respond to microbes and ingested stimuli.
However, intrinsic defects in macrophage and dendritic cell function contribute to the
pathogenesis of inflammatory bowel diseases (IBD), as highlighted by recent genome-wide
association studies. Gastrointestinal macrophages and dendritic cells participate in IBD
development through inappropriate responses to enteric microbial stimuli, inefficient clearance of
microbes from host tissues, and impaired transition from appropriate pro-inflammatory responses
to anti-inflammatory responses that promote resolution. By understanding how intestinal
macrophages and dendritic cells initiate chronic inflammation, new pathogenesis-based
therapeutic strategies to treat human IBD will be elucidated.
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Introduction
In the healthy gastrointestinal tract, homeostasis is an active process that requires a critical
balance of host responses to the enteric luminal contents. Intestinal macrophages and
dendritic cells comprise a unique group of tissue immune cells that are ideally situated at the
interface of the host and the enteric luminal environment to appropriately respond to
microbes and other potential stimuli. Both commensal and pathogenic bacteria are
recognized through conserved molecular microbial patterns by pattern-recognition receptors
(PRRs). Mechanisms by which the host distinguishes commensal from pathogenic bacteria
are not well defined and represent a fundamental gap in the understanding of homeostatic
immune function and IBD.
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How do intestinal DCs and macrophages interact with the microbial environment?
Intestinal macrophages and dendritic cells (DCs) sense conserved molecular patterns on
microbes (pathogen-associated molecular patterns, PAMPs) via germ-line encoded
PRRs.1, 2PRRs are divided into four families based on shared functional domains: toll-like
receptors (TLRs), nucleotide-binding oligomerization domain (NOD), leucine-rich repeat
(LRR) receptors (NLRs), C-type lectin receptors (CLRs), and retinoic acid-inducible gene 1
(RIG-I)-like receptors (RLRs).3 Signaling downstream of each family of PRRs culminates in
activation of central immune response pathways: nuclear factor kappa-light-chain-enhancer
of activated B cells (NF-κB), the mitogen-activated protein kinases (MAPKs), and
interferon regulatory factors (IRFs).4 Upon engagement of PRRs, immune and non-immune
cells produce inflammatory cytokines, type I interferons, chemokines, and antimicrobial
peptides. As a result, neutrophils are recruited and macrophages are activated, leading to the
direct killing and clearance of microbes. Additionally, these inflammatory products induce
the maturation of DCs, promoting the induction of adaptive immune responses. A carefully
orchestrated process, microbial sensing and subsequent immune responses are highly
regulated. Dysregulation of these pathways can lead to both enhanced susceptibility to
infections and development of chronic inflammatory diseases.3
PRR recognition of its cognate PAMPs culminates in the initiation of pathogen-specific
programs designed to eradicate the prevailing insult. But how does the host recognize an
intact microbe and decide which program to initiate? In reality, one microbe has many
different PAMPs, and many PRRs may recognize one PAMP. Additionally, different cell
types express unique sets of PRRs, and each PRR may play fundamentally different roles in
the temporally distinct phases of an infection (i.e., initial infection versus memory response).
The complex crosstalk between PRR families also confers specificity to and regulates each
immune response. Thus, the assembly of a successful immune response to microbes depends
on the context of the infection, the cell types responding to it, and the array of PRRs that are
engaged during the infection.3 Furthermore, the local microenvironment provides contextual
cues to immune cells via cytokines and growth factors produced by host cells and metabolic
products from microbes.5 It is likely through this complex context of recognition that innate
immune cells distinguish between commensal and pathogenic microbes and initiate an
appropriate response program. However the precise mechanism of discernment of helpful
from harmful microbes and regulation of subsequent immune responses and how this relates
to intestinal homeostasis and IBDs remains incompletely understood.
PAMP recognition by PRRs on intestinal macrophages and DCs leads to the efficient
removal of potential stimuli while remaining immunologically nonresponsive. This feature
is unique to intestinal tissue resident macrophages and DCs.6 The importance of remaining
“inflammation anergic” is emphasized by the development of chronic intestinal
inflammation in the absence or dysregulation of macrophage and DC responses to microbial
stimuli.7 Ultimately, inappropriate host responses to the luminal microbiota in genetically
susceptible individuals disrupt homeostasis, leading to development of IBDs.
IBD pathogenesis: A macrophage- and DC-centric view—The pathogenesis of
IBDs, including Crohn's disease (CD) and ulcerative colitis (UC), is multifactorial, and
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encompasses incompletely defined and complex interactions between host immune
responses, genetic susceptibility, environmental factors, and the enteric luminal contents.8
Recent genome-wide association studies have highlighted the importance of host innate
immune responses to microbes in the pathogenesis of IBDs.9 Single nucleotide
polymorphisms (SNPs) associated with increased risk of developing IBDs were identified in
genes involving microbial sensing (NOD2, IRF5, NFKB1, RELA, REL, RIPK2, CARD9, and
PTPN22) and clearance (ATG16L1, IRGM, NCF4), and integrating antimicrobial adaptive
immune responses (IL23R, IL10, IL12, IL18RAP/IL1R1, IFNGR/IFNAR1, JAK2, STAT3,
and TYK2).10 Intestinal macrophages and DCs reside in the lamina propria (LP) and thus are
ideally positioned to continuously sample intestinal luminal contents. LP mononuclear cells
(LPMCs), including macrophages and DCs, are the sentinels and first-responders of the gut-
associated lymphoid tissues (GALT). Additionally, resident LPMCs possess unique
attributes that shape the gastrointestinal tract as a largely tolerant environment while
maintaining effective clearance of microbes. Importantly, LPMCs direct subsequent
adaptive immune responses, thereby regulating local inflammation.
This review will explore how macrophages and DCs help to initiate inflammation in the
gastrointestinal tract by first describing how these cells maintain intestinal homeostasis
under physiologic conditions. Next, the breakdown of homeostasis encouraged by
macrophages and DCs as it pertains to the development of IBDs will be described. Intestinal
macrophage and DC dysfunction is now widely recognized as a central component to the
pathogenesis of IBDs, and understanding this phenomenon is vital to the development of
effective therapies for these debilitating diseases.
Macrophages and DCs in GI Homeostasis
The gut-associated lymphoid tissue (GALT) represents the largest aggregate of lymphoid
tissue in the body. GALT includes various organized collections of immune cells within the
gastrointestinal tract, such as Peyer's patches in the small intestine, and cryp to patches in
the large intestine; and the diffuse arrangement of intestinal mononuclear cells within the
lamina propria. The close proximity of LPMCs to the enteric luminal compartment,
separated by an epithelial cell monolayer, is important for several reasons: LPMCs (1)
sample luminal antigens that gain access to the lamina propria under physiologic conditions
to maintain local and systemic tolerance, and (2) efficiently clear microbes and stimuli that
cross the IEC barrier. Resident LP macrophages demonstrate distinct attributes from
peripheral monocyte populations. While LP macrophages maintain robust microbicidal
effector functions, they do not produce inflammatory mediators upon encountering
microbial stimuli.6 Additionally, LP macrophages promote the transition from protective
inflammatory responses to resolving anti-inflammatory responses upon encountering a
danger signal. Thus, LPMCs are integral to directing appropriate immune responses and
maintaining intestinal homeostasis in the gut.
There remains active debate about the classification and ontogeny of LP macrophages and
LP dendritic cells (LPDCs). The surface integrins CD11b and CD11c are routinely used to
distinguish between macrophages and DCs in peripheral lymphoid tissues (CD11b+CD11c-
and CD11b+/-CD11chigh are characterized as macrophages and DCs, respectively).
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However, the distinction between LP macrophages and LPDCs is less clear, as LP
macrophages express both CD11b and CD11c.6 It has been proposed that differential
expression of CX3CR1 (the receptor for the chemokine fractalkine, CX3CL1) and CD103
(αEβ7 integrin) reliably distinguish between LP macrophages and LPDCs.6, 11
CD103-CX3CR1hi LP macrophages express the classical macrophage marker F4/80,
demonstrate ultrastructural characteristics of macrophages, and under physiologic conditions
do not traffic to draining mesenteric lymph nodes (MLNs) where priming of adaptive
immune responses is initiated. However, there is evidence that CX3CR1hi LP macrophages
travel to MLNs during enteric microbial dysbiosis.12 Conversely, CD103+CX3CR1lo LPDCs
are F4/80- and perform functions typically associated with DC, including constitutive
trafficking to MLN, antigen presentation to T lymphocytes, and inducing gut homing
receptors on T cells. Both LP macrophages and LPDCs express high levels of MHC class II,
demonstrating their ability to interact with and shape adaptive immune responses. While
controversy remains over the exact nature and origin of these LP subsets, for our purposes,
we will classify LP macrophages as CD103-CX3CR1hi and LPDCs as CD103+CX3CR1lo
cells.
Lamina propria macrophages
Macrophages are a highly heterogeneous population of cells that demonstrate a continuum
of activation states. The wide spectrum of macrophage phenotypes is often somewhat
oversimplified into two functional groups: “inflammatory” M1 (high IL-12, low IL-10) and
“wound healing” M2 (low IL-12, high IL-10) macrophages.13 Additionally, a recently
appreciated subset of macrophages that produces high levels of IL-10 is referred to as
“regulatory macrophages.”
Specific combinations of cytokines within the microenvironment polarize macrophages, and
evidence suggests that macrophages maintain considerable plasticity between activation
states. M1 macrophages are polarized by IFN-γ produced by NK and T helper (Th) 1 cells,
TNF-α produced by granulocytes or other antigen presenting cells (APCs) and engagement
of PRRs by PAMPs, which activates suppressor of cytokine signaling 3 (SOCS3) to induce
the M1 phenotype.14-16 M1 macrophages produce pro-inflammatory cytokines (TNFα,
IL-12, IL-6), and reactive oxygen and nitrogen species. Production of these mediators
promotes the differentiation and activation of Th1 and Th17 cells.13, 17-19 The Th1 response
in turn helps macrophages by enhancing their ability to clear intracellular pathogens. While
M1 macrophages are essential for the eradication of intracellular infections, they also
produce pro-inflammatory cytokines implicated in IBD pathogenesis. Furthermore,
unregulated M1 macrophage activity can induce tissue damage, predispose the host to
developing neoplastic lesions, and induce insulin resistance.20, 21
M2 macrophages are polarized by IL-4 produced by granulocytes or Th2 cells in response to
tissue injury and activation by some fungi and parasites and initiation of SOCS2 signaling.13
M2 macrophages produce matrix metalloproteases, growth factors, and demonstrate efficient
phagocytosis of debris without producing pro-inflammatory cytokines. Th2 responses are
aimed at inducing wound healing and clearing parasites, although the exact mechanisms
underlying parasite eradication are unknown. Indeed, down regulation of microbicidal
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functions in M2 macrophages can render the host more susceptible to certain infections.22-27
M2 macrophages are also efficient at recruiting Foxp3+ T regulatory (Treg) cells, which
would further down regulate local immune responses.16 Furthermore, unregulated M2
macrophage activity can promote the development of fibrotic lesions through elaboration of
TGFβ and enhanced allergic responses.28, 29
Regulatory macrophages are polarized by a wide array of signals, including IgG immune
complexes, IL-10, prostaglandins, and apoptotic cells, potentially by activation of the
MAPK extracellular signal-regulated kinase (ERK).13 However, typically two signals are
necessary to induce regulatory macrophages, such as engagement of PRRs by PAMPs.
Regulatory macrophages differ from M2 macrophages in that they do not produce
extracellular matrix components but express high levels of costimulatory molecules (CD80,
CD86) necessary for the activation of T cells. Like M2 macrophages, regulatory
macrophages produce high amounts of the anti-inflammatory cytokine IL-10 and can render
the host more susceptible to certain infections.30-36 Furthermore, unregulated regulatory
macrophage activity may also play a role in the induction of neoplastic lesions by
dampening anti-tumor macrophage defenses and promoting angiogenesis.37, 38
LP macrophages are unique tissue resident macrophages characterized by the inability to
produce inflammatory cytokines in response to microbial stimuli. However, these cells
maintain robust phagocytic and microbicidal effector capabilities. The tolerant phenotype of
LP macrophages is likely conditioned by locally produced IL-10 and TGF-β.39, 40 However,
the ontogeny of these cells is unknown. LP macrophage maintenance may depend on local
proliferation rather than repopulation from migrating blood monocytes, but this is
experimentally difficult to determine due to the extremely low turnover rate of these cells.
Additionally, the context during which blood monocytes are recruited to the intestines may
determine the final phenotype of the LP macrophages. During non-inflammatory
homeostatic conditions, Ly6Chi monocytes almost exclusively repopulate the lamina propria
with CD11c+ (F4/80hiCX3CR1hiCD11b+CD103-) LP macrophages.41 In contrast, under
inflammatory conditions, Ly6Chi monocytes recruited to the lamina propria differentiate
into CD103+CX3CR1intCD11b+ DCs that produce high levels of the inflammatory cytokines
IL-12, IL-23, iNOS, and TNF-α.41
CX3CR1hi LP macrophages extend dendrites between IECs to sample luminal antigens and
promote local tolerance through constitutive production of the anti-inflammatory cytokine
IL-10,42 the absence of an inflammatory response to activating stimuli, very low expression
of co-stimulatory molecules CD80, CD86 and of the macrophage activating receptor
CD40.40 Although these cells that sample the luminal environment were originally defined
as DCs43, recent work supports that they may represent a macrophage population.44 IL-10
produced by LP macrophages promotes the persistence of Foxp3 expression in Treg cells in
the intestine.45 Additionally, CX3CR1hi LP macrophages participate in the induction of
systemic oral tolerance.42 It has been suggested that CX3CR1hi LP macrophages sample
luminal antigens and deliver them to CD103+ LPDCs, which are then able to traffic to MLN
to prime adaptive immune responses.46 However, there is recent compelling evidence that
CX3CR1hi LP macrophages do traffic to MLNs in a CCR7-dependent manner during
dysbiosis of the enteric microbiota.12
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Unique intracellular signaling pathways contribute to the inflammation anergic characteristic
of LP macrophages; however, it remains unclear exactly what makes LP macrophages
distinct from circulating monocytes and other tissue resident macrophages. Additionally,
inflammation anergic LP macrophages are distinct from the more widely studied endotoxin-
resistant macrophages. For one, LP macrophages do express PRRs, contrary to conventional
thought. Recent studies suggest that the enteric microbiota are not necessary to program LP
macrophages to express high amounts of the anti-inflammatory cytokines IL-10 and TGF-
β.47, 48 One enticing candidate for inducing LP macrophage nonresponsiveness to PAMPs is
IL-10. Importantly, IL-10-deficient mice49 and mice with myeloid-specific ablation of the
IL-10 signaling molecule STAT350 develop spontaneous colitis reminiscent of human IBD.
Additionally, blocking IL-10 restores PAMP responsiveness in LP macrophages. Our lab
described a mechanism for IL-10-mediated suppression of IL-12p40 via altering histone
acetylation and RNA polymerase II accessibility to the Il12b promoter,48 suggesting that
IL-10 directly inhibits the production of pro-inflammatory cytokines in response to PAMP
stimulation. IL-10 additionally exerts its anti-inflammatory effects on the innate immune
system by regulating transcriptional elongation,51 microRNA induction,52 mRNA
stability,53 and transcriptional repressors and corepressors.54
Additionally, the phosphoinositide 3-kinase (PI3K) pathway negatively regulates signaling
through TLRs in macrophages. In particular, the p110δ isoform of PI3K is enriched in
leukocytes and regulates IL-12p40 production in LP macrophages in response to microbial
stimulation. PI3K p110δ is indispensable for intestinal homeostasis as mice harboring an
inactivating point mutation in p110δ (p110δ kinase-dead, or p110δKD mice) develop
spontaneous colonic inflammation. LP macrophages from p110δKD mice produce
significantly more IL-12p40 and less IL-10 upon stimulation with heat-killed Escherichia
coli.55 Thus, a loss in the critical negative regulation of TLR signaling results in the
disruption of intestinal homeostasis.
Lamina propria dendritic cells
Broadly speaking, DCs are professional APCs with the ability to initiate adaptive immune
responses against pathogens. Like macrophages, DCs comprise a heterogeneous population
of cells with functional diversity. DCs originate from blood monocytes or a common DC
progenitor (CDP) in the bone marrow at steady state. DCs repopulating tissues from
monocyte precursors rely on granulocyte-macrophage colony stimulating factor (GM-CSF)
for local proliferation.56 Conventional DCs (cDCs) arising from the CDP express high levels
of CD11c, varying levels of CD8α and CD11b, and reside in secondary lymphoid tissues.
Plasmacytoid DCs (pDCs) also originate from the CDP and are specialized in the production
of type I interferons. In addition to functional subsets of DCs, the maturation state of DCs
has important implications in immunity. Mature DCs that have previously encountered
microbial products and inflammatory stimuli are highly specialized for antigen presentation.
Thus, mature DCs express high levels of co-stimulatory molecules and tend to reside in
secondary lymphoid organs where they are ideally positioned to prime antigen-specific T
cells.57 On the other hand, immature DCs demonstrate low surface expression of co-
stimulatory molecules and constitutively migrate in low numbers to lymph nodes, perhaps to
maintain tolerizing signals there.57, 58
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LPDCs also comprise a heterogeneous group of cells in the intestines. Only recently has it
also been appreciated that LPDCs play an active and direct role in maintaining peripheral
tolerance to self and intestinal luminal antigens. Like LP macrophages, LPDCs represent a
spectrum of functionally distinct phenotypes. CD8α+pDCs in the LP are capable of inducing
regulatory T cells and supporting their function.59 However, most LPDCs are
CD11b+CD8α-, but CD11b-CD8α+ and CD11b-CD8α- subsets are also present. These DCs
weakly stimulate antigen-specific T cell proliferation and constitutively express IL-10 and
type I interferons.60 Furthermore, LPDCs are divided into CD103+ and CD103- (E-cadherin
receptor) populations, each demonstrating distinct functions. CD103+ LPDCs are able to
induce Foxp3-expressing Treg cells,61-63 whereas CD103- LPDCs are efficient at inducing
Th17 cells when stimulated with flagellin or microbial ATP.64-66 While the Th17 response
is important for antimicrobial immunity, dysregulation of Th17 lymphocytes and cytokines
is implicated in a number of autoimmune disorders.67
CD103+ LPDCs represent a population of tolerizing innate immune cells that express the
enzyme retinaldehyde dehydrogenase (RALDH), which produces retinoic acid (RA) from
retinaldehyde, and the important regulatory cytokine TGF-β. Both CD103+ LPDC-produced
RA and TGF-β are necessary for the induction of Treg lymphocytes in the intestine.61-63
Additionally, CD103+ LPDCs produce indoleamine 2,3-dioxygenase (IDO), which
participates in the induction of Treg cells and suppression of Th cell proliferation.68
The induction of CD103 expression in LPDCs is dependent on the vitamin A metabolite RA
and the local production of factors from IECs and stromal cells. IECs induce CD103
expression in LPDCs in an RA-, TGF-β-, and contact-dependent manner.69 In addition to
TGF-β, stromal cells in the LP constitutively produce prostaglandin E2, which inhibits the
production of pro-inflammatory cytokines in DCs.70 Importantly, thymic stromal
lymphopoietin (TSLP) produced by IECs conditions LPDCs to induce Th2 cell
differentiation, although its necessity in inducing and maintaining Treg cells is
controversial.69 Nonetheless, TSLP produced by IECs confers a homeostatic phenotype on
LPDCs to protect mice from colitis.69, 71-73 CD103+LPDC differentiation is dependent on
Notch2 signaling, as Notch2-/- mice demonstrate a selective loss of CD11b+CD103+
LPDCs.74 Furthermore, the preferential expansion of CD103+ LPDCs depends on the DC
differentiating molecule Fms-related tyrosine kinase-3 ligand (Flt3L).75 The function of
CD103+ LPDCs depends on several factors. Dietary vitamin A induces RALDH expression
in CD103+ LPDCs76 and is necessary for these cells to imprint T cells with gut-homing
receptors.77, 78
Aside from inducing Th17 differentiation, CD103- LPDCs are involved in the induction of
immunoglobulin A (IgA) class switching of B lymphocytes, both in the Peyer's patches and
intestinal LP. IgA is abundantly produced in the intestine and prevents the harmful effects of
bacterial overgrowth and bacterial adhesion to IECs in the intestinal lumen.79 In the isolated
lymphoid follicles of the LP, CD70+ LPDCs expressing TLR5 and any of various ATP
receptors induce IgA class switching in RA-dependent and T lymphocyte-independent
manners.64 LPDCs that produce iNOS and TNF also support IgA class switching.80
Cytokines produced by IECs, stromal cells, and LPDCs, including B cell activating factor
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(BAFF), a proliferation-inducing ligand (APRIL), IL-4, TGF-β, and IL-10, support the
induction, maintenance, and expansion of IgA+ plasma cells.81
LPDCs have a higher turnover rate than LP macrophages due to frequent trafficking to MLN
to present antigen to naïve T lymphocytes.57 Evidence suggests that CD103+CD11b- LPDCs
are replenished by DC-committed precursors (pre-cDC) in a Flt3L-dependent manner,82
whereas CD103-CD11b+ LPDCs are derived from circulating Ly6Chi monocytes in a GM-
CSF-dependent manner.83 Additionally, the preferential expansion of regulatory CD103+
LPDCs is also Flt3L-dependent.75 The conditions under which precursors are recruited to
and the existing microenvironment of the LP likely determine the final phenotype of
LPDCs. For instance, under steady-state conditions F4/80loCD103+CD11c+ LPDCs are
repopulated from circulating Ly6Chi monocytes, however during colitis Ly6Chi monocytes
repopulated inflammatory CD103-CX3CR1intCD11b+ LPDCs and exacerbated
inflammation.41, 83
Summary
Populations of macrophages and dendritic cells within the intestinal LP are diverse. LP
macrophages and LPDCs interact with the intestinal environment and luminal contents to
maintain homeostasis through the production of protective mediators, dampening of pro-
inflammatory responses, and the active induction of adaptive immune tolerance. Distinct
functional populations of LP macrophages and LPDCs actively promote tolerance while
others have the propensity to enhance protective inflammatory responses to foreign antigens.
However, an imbalance in any of these physiologic processes may tip the balance toward
chronic intestinal inflammation and IBD, as we will explore in the next section.
Macrophages and DCs in IBD Pathogenesis
Murine Experimental IBD
There are a number of phenotypic and functional alterations described in LP macrophages
and LPDCs during IBD development. Recent research highlights a central role for
macrophages and DCs in the pathogenesis of colitis, as numerous IBD susceptibility SNPs
affecting innate immune cell functions have been identified.9 Additionally, the selective
depletion of macrophage and DC subsets in mouse models of colitis has been particularly
informative about the protective and pathogenic roles innate immune cells play during
discrete stages of disease pathogenesis. Lymphocyte deficient mice (severe combined
immunodeficiency, SCID) develop colitis upon treatment with the intestinal irritant dextran
sodium sulfate (DSS), suggesting that macrophages and DCs are pathogenic in this model in
the absence of mature lymphocytes.84 Depletion of phagocytes in Il10-/- mice,85 and
blocking myeloid cell recruitment in both 2,4,6-trinitrobenzene sulfonic acid (TNBS)-
induced86 and T cell adoptive transfer87 colitis ameliorate disease, as does selective
depletion of LPDCs during DSS colitis.88, 89 Contrary to these findings, depletion of LP
macrophages and LPDCs prior to the induction of DSS colitis results in exacerbated
disease.90, 91 Furthermore, different subsets of macrophages and DCs have distinct effects
on the severity of colitis in animal models. M2 polarized macrophages protect mice from
DSS colitis, whereas M1 polarized macrophages contribute to disease pathogenesis.92-94
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Selective expansion of CD103+ LPDCs by Flt3L protects TNFΔARE mice from ileitis,75 but
E-cadherin-expressing DCs increase colonic pathology in DSS colitis.95 Thus, the
protective/pathogenic role of distinct macrophage and DC populations in the LP remains an
active area of investigation.
In general, there are three ways in which defects in innate immune cell functions can initiate
IBD development: (1) by responding inappropriately to normally benign stimuli such as
commensal microbes, (2) by inefficiently clearing microbes, leading to chronic immune
stimulation, and (3) by failing to switch from an appropriate pro-inflammatory response to
an inflammation-resolving anti-inflammatory response. Here we will discuss each of these
defects and how each leads to chronic inflammation and IBD.
The enteric microbiota is essential for the development of colonic inflammation in most
murine models of colitis.96, 97 Perturbations in the negative regulation of innate immune
responses to stimuli enhance susceptibility to colitis development. The well-characterized
Il10-/- murine model of spontaneously developing colitis demonstrates the necessity of the
potent anti-inflammatory cytokine IL-10 in the maintenance of intestinal homeostasis.49
Indeed, LP macrophages derived from germ free (GF) Il10-/- mice produce increased
IL-12p40 compared to GF WT LP macrophages at baseline, suggesting that IL-10 is the
critical driver of the LP macrophage phenotype.48 Furthermore, IL-10 produced by CD11b+
LP macrophages is necessary for the maintenance of Foxp3 expression in Treg cells and
protection from colitis.45 The IL-10- and microbiota-inducible nuclear transcription factor,
interleukin-3 regulated (NFIL3) negatively regulates IL-12p40 production in LP
macrophages and has been recently implicated in intestinal homeostasis.98 Thus, studying
the regulation of IL-10 production and its downstream signaling effects is crucial to
understanding intestinal homeostasis.
IL-10-independent regulation of innate immune responses also contributes to intestinal
homeostasis. One negative regulator of intestinal macrophage activation is paired
immunoglobulin-like receptor B (PIR-B). PIR-B is expressed on colonic LP macrophages, B
cells, and neutrophils and contains several immunoreceptor tyrosine-based inhibitory motifs
(ITIMs) that activate intracellular phosphatases, negatively regulating TLR signaling.99 PIR-
B is highly upregulated on LP macrophages following DSS administration in mice.
Furthermore, PIR-B-deficient (Pirb-/-) macrophages produce significantly more TNFα and
IL-6 in response to Escherichia coli, and WT mice reconstituted with Pirb-/- macrophages
demonstrate increased susceptibility to DSS colitis. PIR-B expression is also important in
human intestinal biology, as LP mononuclear cells from both healthy controls and patients
with UC express immunoglobulin-like transcript-2/leukocyte Ig-like receptor-1 (ILT-2/
LIR-1), a human homologue of PIR-B. Our lab recently described spontaneous colitis
development in mice harboring a kinase-dead phosphoinositide 3-kinase (PI3K) catalytic
subunit p110δ (p110δKD), a potent negative regulator of TLR responses in macrophages.55
CD11b+ LPMCs from p110δKD mice produced increased pro-inflammatory cytokines
(IL-12p40, IL-23) and decreased anti-inflammatory IL-10 in response to enteric microbes
compared to CD11b+ LPMCs from WT mice. Conversely, triggering receptor expressed on
myeloid cells-1 (TREM-1) amplifies TLR-induced inflammatory responses in macrophages,
and blocking its activity attenuates murine colitis.100, 101 Indeed, resident LP macrophages
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do not express TREM-1 but abundant TREM-1-expressing LP macrophages can be found in
patients with IBD.102, 103 Thus, unrestrained pro-inflammatory responses of LP
macrophages and LPDCs participate in the induction of chronic inflammation by continued
recruitment of inflammatory cells, inducing altered barrier function of the IEC layer, and
promoting pathogenic adaptive immune responses.
The enteric microbiota interacts with host immune cells to induce protective anti-
inflammatory responses and maintain intestinal homeostasis. Dysregulation of these
protective pathways, either by enteric microbial dysbiosis or intrinsic defects in macrophage
and DC responses to stimuli, may underlie IBD pathogenesis. Short chain fatty acids
(SCFAs) are anti-inflammatory metabolites produced by specific phyla of enteric bacteria
(Bacteroidetes, Firmicutes).104 When DSS colitis is induced in immune cell-specific
Gpr43-/- mice (a host receptor for SCFAs), colonic inflammation is exacerbated, pointing to
the beneficial anti-inflammatory effect of SCFAs in the colon.105 Interestingly, bacteria also
actively suppress intestinal inflammatory responses, although a bacterium can exploit this to
promote its pathogenicity. Citrobacter rodentium and Helicobacter pylori express bacterial
proteins with domains similar to host ITIMs.106 ITIMs negatively regulate immunoreceptor
signaling pathways in immune cells, and bacterial ITIM-like-containing proteins dampen
immune responses in murine colons. On the other hand, analysis of the enteric microbiota of
patients with IBD demonstrates decreased biodiversity, decreased proportions of Firmicutes,
and increased Gammaproteobacteria.107 While it is unknown whether enteric dysbiosis in
IBD patients contributes to or is a consequence of colonic inflammation, researchers
demonstrate reproducible increases in bacteria with unique abilities to adhere and invade
mucosal cells in patients with IBD (i.e., adherent-invasive E. coli),108 as well as decreases in
bacteria capable of producing protective SCFAs.109 Furthermore, it was recently shown that
E. coli is especially adept at using nitrates as electron acceptors, supporting its selective
growth during intestinal inflammation, when nitrates are produced in abundance.110 This
suggests that the interplay between host and bacteria actively shapes intestinal homeostasis
and participates in IBD pathogenesis.
Both macrophages and DCs actively promote the transition from inflammation to the return
to homeostasis after immune system activation, and non-resolving inflammation is
associated with many chronic diseases, including IBD.111 A study found that the pro-
resolution mediator prostaglandin D2 (PGD2) was upregulated only in UC patients who had
achieved long-term remission, suggesting that intact pro-resolution pathways are necessary
to halt damaging intestinal inflammation.112 Additionally, a SNP associated with low
expression of the immune cell ectonucleotidase CD39, which generates the pro-resolving
mediator adenosine, is associated with CD.113 Immune cells are major contributors of
extracellular adenosine at inflammatory sites. Adenosine interacts with its receptor A2B on
macrophages and DCs to inhibit pro-inflammatory cytokine production, expression of co-
stimulatory molecules, and induction of T lymphocyte proliferation while increasing IL-10
production.114
Other pro-resolving soluble mediators with diverse effects on macrophages and DCs are
resolvins, lipoxins, protectins, and maresins.115 These mediators are derived from
polyunsaturated fatty acids (PUFAs), and both CD and UC patients have demonstrated
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deficiencies in these resolving mediators.116, 117 Interestingly, there was found to be a very
low incidence of IBD among a population in Northwest Greenland that consumes high
amounts of PUFAs, suggesting that dietary precursors of pro-resolving factors helps to
prevent chronic gastrointestinal inflammation.118 PUFA-derived mediators enhance the
capacity of macrophages and DCs to promote the resolution of inflammation by inducing
efficient phagocytosis of apoptotic granulocytes and debris, preventing further recruitment
of neutrophils, inducing anergy or deletion of effector T lymphocytes, and promoting repair
of local damage.115 Treatment with resolvin E1 ameliorates pathology in two experimental
murine models of colitis, illustrating the powerful effects of PUFA-derived mediators on
resolving inflammation.119, 120
Macrophages and DCs additionally respond to resolving mediators by switching to unique
“resolution phase” phenotypes. DCs generated in the presence of resolvin E1 demonstrate
decreased expression of co-stimulation molecules, TNF-α, and IL-12, while inducing
antigen-specific CD4+ T lymphocyte apoptosis via IDO production and activation.121 A
defining distinction of resolution phase DCs from tolerogenic DCs is the continued
expression of CCR5, which enhances chemotaxis toward inflammatory sites, without
upregulation of CCR7, which induces chemotaxis to lymph nodes, on resolution phase
DCs.121 Similarly, resolution phase macrophages demonstrate a distinct phenotype from
both M1 and M2 macrophages. Like M2 macrophages, resolution phase macrophages
express high levels of molecules associated with the recognition and clearance of apoptotic
cells, TGF-β, IL-10, and arginase 1.122, 123 However, resolution phase macrophages also
possess features of M1 macrophages, such as expression of iNOS, COX2, and CCR5.122, 123
It is likely that local factors condition both macrophages and DCs to switch phenotypes and
promote the resolution of inflammation, and that generation of these local factors or innate
immune cell responses to these factors are defective in IBD.
Human IBD
In human IBD, inflammatory lesions demonstrate an increase in accumulation of
macrophages that display enhanced expression of co-stimulatory molecules (CD80, CD86)
and macrophage activating receptors (CD40),124 TLRs,125 triggering receptor expressed on
myeloid cells-1 (TREM-1),101, 102 and CD14.103, 126 Likewise, there are higher frequencies
of LPDCs positive for markers of mature DCs (CD83, S-100, CD40)127-130 and for PRRs
(CD209, TLR2/4) found in patients with IBD.128, 129Interestingly, IECs from patients with
CD secreted less TSLP, suggesting that the conditioning factors produced by IECs and
stromal cells in the intestine that are necessary for inducing homeostatic LPDCs are
deficient in IBDs.72 Indeed, LPDCs from IBD patients also produce significantly more pro-
inflammatory cytokines (IL-12, IL-6, IL-8, TNF-α) compared to those from healthy
controls.129, 130 Furthermore, there is an increase in frequency of LP pDC from IBD
patients.131 However, stimulated peripheral blood pDC from IBD patients secrete
significantly less IFN-α compared to those from healthy controls, suggesting that a decrease
in functional tolerogenic pDC in IBD patients contributes to disease pathogenesis.131, 132
There is accumulating evidence that inappropriate macrophage and DC responses to the
enteric microbiota contribute to human IBD pathogenesis.8 These include both inadequate
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protective and enhanced pathogenic responses to such stimuli. Macrophages isolated from
both CD and UC patients demonstrate altered cytokine production in response to bacterial
challenge: CD macrophages produce more pro-inflammatory IL-23 but less of the protective
cytokine IL-10, whereas UC macrophages constitutively produce high levels of the pro-
inflammatory cytokine IL-12.133 This may be in part due to impaired regulation of TLR-
induced inflammatory responses in macrophages. For instance, patients with IBD
demonstrate significantly decreased expression of intestinal NFIL3, an IL-10- and
microbiota-induced transcriptional repressor of IL-12p40 expression, compared to tissue
from healthy, non-inflamed control patients.98 Additionally, increased numbers of TREM-1-
expressing LP macrophages are found in intestinal tissue from patients with IBD compared
to tissue from control patients.102 TREM-1 critically amplifies TLR-induced inflammatory
responses of macrophages and is implicated in IBD pathogenesis. Conversely, LP
macrophages from IBD patients produce less of the cytokine G-CSF, which is protective in
experimental models of colitis, in response to the probiotic Lactobacillus rhamnosus GR-1
compared to those from healthy controls.134
There has long been evidence that patients with IBD demonstrate impaired ability to
eradicate bacteria,135 and antibiotic therapy in certain clinical situations is efficacious for the
induction and maintenance of remission in IBD.136, 137 The human IBD susceptibility
polymorphisms associated with NOD2 and ATG16L1 encode proteins involved in the
autophagy pathway and lead to defective bacterial clearance.138 Macrophages isolated from
patients with CD demonstrate decreased reactive oxygen species (ROS) production and
impaired eradication of bacteria.139, 140 Additionally, peripheral blood monocytes isolated
from patients with both CD and UC demonstrate decreased phagocytosis and killing of
bacteria.141 Perhaps the most compelling evidence of the link between bacterial persistence
and IBD is the long list of primary immunodeficiencies, such as chronic granulomatous
disease (CGD), associated with IBD-like clinical manifestations.142-146 Approximately 50%
of patients with CGD, in which phagocyte ROS production and bacterial clearance are
greatly impaired, develop IBD-like manifestations that share clinical and pathological
features of CD.142 Bacterial persistence and chronic stimulation of macrophages and DCs
may contribute to IBD development by producing increased pro-inflammatory cytokines
that shape pathogenic adaptive immune responses.
Conclusions
Innate immune cells are central to the pathogenesis of IBD, as susceptibility loci have been
identified in genes encoding for innate immune cell functions.9 We are beginning to
understand how macrophages and DCs maintain homeostasis in the gastrointestinal tract, a
uniquely tolerant environment. Homeostasis requires an active process, and disruption of
this balance contributes to chronic inflammation and IBD development. Defects in how
macrophages and DCs respond to enteric antigens, eradicate bacteria, and induce resolution
of inflammation underlie IBD pathogenesis (See Figure 1 for summary of pathways and
phenotypes). By understanding these pathways, we will be able to exploit them for the
development of novel and more effective therapies.
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Abbreviations
APC antigen presenting cell
CARD caspase recruitment domain
CD Crohn's disease
cDC conventional dendritic cell
CLR C-type lectin receptor
DC dendritic cell
DSS dextran sulfate sodium
Flt3 Fms-like tyrosine kinase 3
Flt3L Flt3 ligand
GALT gut-associated lymphoid tissue
GM-CSF granulocyte-macrophage colony stimulating factor
IBD inflammatory bowel disease
IDO indoleamine 2,3-dioxygenase
IEC intestinal epithelial cell
Ig immunoglobulin
IRF interferon regulatory factor
ITIM immunoreceptor tyrosine-based inhibition motif
LP lamina propria
LPDC lamina propria dendritic cell
LPMC lamina propria mononuclear cell
LRR leucine-rich repeat
MAPK mitogen-activated protein kinase
MLN mesenteric lymph node
MyD88 myeloid differentiation primary response gene 88
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells
NFIL3 nuclear factor, interleukin 3 regulated
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NLR nucleotide-binding oligomerization domain, leucine-rich repeat receptor
PAMP pathogen-associated molecular pattern
pDC plasmacytoid dendritic cell
PI3K phosphoinositide 3-kinase
PIR-B paired immunoglobulin-like receptor B




ROS reactive oxygen species
SNP single nucleotide polymorphism
TAK1 TGF-β-activated kinase 1
Th T helper cell
TIR toll/interleukin 1 receptor
TLR toll-like receptor
Treg regulatory T cell
TREM-1 triggering receptor expressed on myeloid cells-1
TRIF TIR-domain-containing adapter-inducing interferon-β
TSLP thymic stromal lymphopoietin
UC ulcerative colitis
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LPMCs affect intestinal homeostasis in health and disease. LPMCs participate in
maintaining intestinal homeostasis and in initiating disease when homeostasis is perturbed.
(1) CD103–CX3CR1high LPMCs extend dendrites across the IEC barrier to sample luminal
bacteria and antigens. (2) IECs and stromal cells produce local factors that condition LPMCs
to be tolerant. (3) LP macrophages constitutively produce high levels of IL-10, which is
necessary for the maintenance of Foxp3 expression in LP Tregs. (4) CD103+CX3CR1low
LPDCs produce TGF-β and RA to induce Treg cells and imprint gut-homing receptors in
adaptive immune cells. (5) CD103+CX3CR1low LPDCs induce IgA class switching in B
cells. IgA is important in controlling the growth and composition of the enteric microbiota.
(6) During perturbation of intestinal homeostasis, the enteric microbiota demonstrates
dysbiosis. Additionally, the mucous layer just superficial to the IEC layer can break down,
exposing IECs to the microbiota and inducing IECs to produce inflammatory cytokines. (7)
Defects in intracellular bacterial clearance leads to persistent stimulation of LPMCs and
induction of proinflammatory cytokines. IL-12 and IL-23 support the maintenance and
differentiation of Th1 and Th17 cells, respectively. (8) CD103+CX3CR1low cells become
inflammatory, producing increased amounts of IL-12, IL-6, IL-8, and TNF-α, supporting the
differentiation of pathogenic T cells and the recruitment of inflammatory cells to the
intestines.
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